Erdosteine for non-alcoholic fatty liver disease
Part of Digestive system clinical trials.
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with fatty liver disease using an ultrasound
- You are not pregnant or breastfeeding
- You do not drink heavily (more than 2 drinks per day for men, 1 for women)
- You do not have other liver diseases like hepatitis or drug-induced liver injury
- You do not have kidney disease, parathyroid problems, or an allergy to erdosteine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called cilostazol can help treat nonalcoholic fatty liver disease. It is for adults who have fatty liver seen on an ultrasound and do not have other liver problems.
This study tests a medicine called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD). If you have a fatty liver and no other liver or kidney conditions, this trial may explore whether this drug is safe and effective for you.
This trial tests special food products made from plant protein to see if they are well-tolerated and if they can improve your cholesterol and fat levels in the blood. If you have fatty liver disease, this could be a way to improve your health through diet.
This study tests an investigational supplement called Godex Carnitine Orotate Complex to see if it helps people with nonalcoholic fatty liver disease (NAFLD) lower their liver enzymes and reduce liver fat. It may be a good option if you have elevated liver enzymes and evidence of fat in your liver.
This study tests a medicine commonly used for diabetes to see if it can help people with fatty liver disease. The medicine may reduce fat in the liver and improve liver health.
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Hear when a new Fatty Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.